These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1977779)

  • 1. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group.
    Lichstein E; Hager WD; Gregory JJ; Fleiss JL; Rolnitzky LM; Bigger JT
    J Am Coll Cardiol; 1990 Nov; 16(6):1327-32. PubMed ID: 1977779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group.
    Goldstein RE; Boccuzzi SJ; Cruess D; Nattel S
    Circulation; 1991 Jan; 83(1):52-60. PubMed ID: 1984898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.
    Lobmeyer MT; Gong Y; Terra SG; Beitelshees AL; Langaee TY; Pauly DF; Schofield RS; Hamilton KK; Herbert Patterson J; Adams KF; Hill JA; Aranda JM; Johnson JA
    Pharmacogenet Genomics; 2007 Apr; 17(4):277-82. PubMed ID: 17496726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
    Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Captopril adjuvant therapy to beta-blockers and nitrates improves post-myocardial infarction left ventricular performance.
    Kyriakidis M; Antonopoulos A; Georgiou E; Santas P; Bakirtzis C; Toutouzas P
    Eur Heart J; 1996 Jun; 17(6):864-73. PubMed ID: 8781825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
    Pfeffer MA; Braunvald Iu; Moĭe LA; Basta L; Braun EDzh ; Kaddi TE; Dévis BR; Geltman EM; Goldman S; Fleĭker GS
    Kardiologiia; 1993; 33(12):14-23, 3. PubMed ID: 7910865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Doughty RN; Whalley GA; Gamble G; MacMahon S; Sharpe N
    J Am Coll Cardiol; 1997 Apr; 29(5):1060-6. PubMed ID: 9120160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    Yndigegn T; Lindahl B; Mars K; Alfredsson J; Benatar J; Brandin L; Erlinge D; Hallen O; Held C; Hjalmarsson P; Johansson P; Karlström P; Kellerth T; Marandi T; Ravn-Fischer A; Sundström J; Östlund O; Hofmann R; Jernberg T;
    N Engl J Med; 2024 Apr; 390(15):1372-1381. PubMed ID: 38587241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
    Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
    Trials; 2020 May; 21(1):415. PubMed ID: 32446298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function.
    Siu CW; Pong V; Jim MH; Yue WS; Ho HH; Li SW; Lau CP; Tse HF
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):675-80. PubMed ID: 20132502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics.
    Kristensen AMD; Munkhaugen J; Halvorsen S; Olsen MH; Bakken A; Sehested TSG; Ruddox V; Lange T; Fagerland MW; Torp-Pedersen C; Prescott E; Atar D
    Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):175-183. PubMed ID: 38017624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Kennedy HL; Brooks MM; Barker AH; Bergstrand R; Huther ML; Beanlands DS; Bigger JT; Goldstein S
    Am J Cardiol; 1994 Oct; 74(7):674-80. PubMed ID: 7942525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
    Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
    Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.
    Spargias KS; Hall AS; Greenwood DC; Ball SG
    Heart; 1999 Jan; 81(1):25-32. PubMed ID: 10220541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
    Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
    Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction.
    Horiuchi Y; Tanimoto S; Aoki J; Nakajima H; Hara K; Tanabe K
    Int J Cardiol; 2016 Oct; 221():765-9. PubMed ID: 27428318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group.
    Bonarjee VV; Carstensen S; Caidahl K; Nilsen DW; Edner M; Lindvall K; Snapinn SM; Berning J
    Am Heart J; 1996 Jul; 132(1 Pt 1):71-7. PubMed ID: 8701878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
    Wolf SC; Buck-Müller N; Görner S; Risler T; Brehm BR
    Med Klin (Munich); 2003 Jan; 98(1):1-6. PubMed ID: 12540987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.